Canaccord Genuity Maintains Hold and Raises Price Target on ISIS Pharmaceuticals (ISIS)

Article Stock Quotes (1) Comments (0)

Today analysts at Canaccord Genuity maintained a Hold rating on ISIS Pharmaceuticals (NASDAQ: ISIS) and raised their price target to $11.00 (from $9.00). The increased PT ascribes greater value to the company's pipeline.

"We continue to view ISIS's pipeline as progressing nicely, with the next lead product, TTR (TTR amyloidosis, partnered with GSK) to enter P3 for familial polyneuropathy in H2," said analyst Salveen Richter.

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $13.19 yesterday, with a 52 week range of $6.25-$14.05.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• Wells Fargo Upgrades ProLogis (PLD) to Outperform
• UPDATE: UBS Starts Insmed (INSM) at Buy

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?